secwatch.observer — SEC 8-K summary
======================================

Issuer:     DNA X, Inc. (SONM)
CIK:        0001178697
Form:       8-K
Filed at:   2025-10-31T23:59:59+00:00
Accession:  0001493152-25-020309
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sonim Q3 revenue $16.2M (+45% seq), net loss narrows to $4.8M; asset sale to NEXA for $15M on track for Q4 close
--------------------------------------------------------------------------------

- Net revenue $16.2M, up 45% sequentially from Q2; GAAP net loss $4.8M vs $7.5M in Q2.
- Adjusted EBITDA negative $2.0M, improving from negative $3.2M in Q2.
- Entered definitive agreement to sell substantially all assets to NEXA for $15M cash plus up to $5M earn-out; expected close late Q4 2025.
- Reverse stock split 1-for-18 effected Oct 27, 2025 to regain Nasdaq compliance.
- Cash $2.1M; received $4.8M net proceeds from equity offerings during Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178697/000149315225020309/0001493152-25-020309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178697/000149315225020309/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-020309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer